Matthew Brendon Might

Matthew Brendon Might, Ph.D., is a Senior Lecturer on Biomedical Informatics (Part-time) at Harvard Medical School in the Department of Biomedical Informatics within the Faculty of Medicine. He also holds full-time positions at the University of Alabama at Birmingham (UAB), where he is the Director of the Hugh Kaul Precision Medicine Institute, the Hugh Kaul Endowed Chair of Personalized Medicine, and a Professor of Internal Medicine and Computer Science. His work spans computational biomedicine, AI in healthcare, and rare disease research.

• Senior Lecturer on Biomedical Informatics, Harvard Medical School (Part-time)
• Director, Hugh Kaul Precision Medicine Institute, UAB
• Hugh Kaul Endowed Chair of Personalized Medicine, UAB
• Professor of Internal Medicine and Computer Science, UAB
• Former Strategist, Executive Office of the President (White House), 2016–2018

Matthew Might’s research is centered on precision medicine, particularly for rare diseases, cancer, and chronic conditions. He leverages computer science, data science, and AI to improve diagnosis, prevention, and therapeutics. His personal motivation stems from his son’s diagnosis with NGLY1 deficiency, driving his work in rare disease discovery and personalized treatment strategies. He is deeply involved in developing AI tools like mediKanren to uncover hidden knowledge in biomedical data.

His recent publications reflect a strong trajectory in rare disease modeling (e.g., NGLY1 organoids), AI-driven diagnostics, long COVID, and population genomics. Articles frequently involve patient-derived stem cells, computational phenotyping, and data integration across large networks such as the Undiagnosed Disease Network. Themes include the intersection of AI and clinical care, health disparities, and the scalability of precision medicine.

Might has been a Principal Investigator or Co-Principal Investigator on multiple NIH-funded projects, including:

• Diagnosing the Unknown for Care and Advancing Science (DUCAS) (NIH U2CNS132415)
• UAB Pilot Center for Precision Animal Modeling (C-PAM) (NIH U54OD030167)
• Doc Sherlock: An Autonomous Relay Agent (NIH OT2TR003435)
• Biomedical Data Translator (NIH OT2TR002517, as PI)
• Undiagnosed Disease Network Phase II (NIH U01HG007530)

He is the co-founder and Chief Scientific Officer of NGLY1.org and a Scientific Advisor to Pairnomix (acquired by Q State Biosciences). His leadership in national policy, including the White House Precision Medicine Initiative, underscores his impact beyond academia. He mentors students and researchers through collaborative projects and has contributed significantly to the advancement of data-driven rare disease therapeutics.

Might leads research initiatives through the Hugh Kaul Precision Medicine Institute at UAB and collaborates extensively with the Department of Biomedical Informatics at Harvard Medical School. His work is highly interdisciplinary, involving teams in bioinformatics, clinical genetics, AI, and translational science, often in partnership with the NIH and other precision medicine consortia.